GRIFOLS ITALY operating for over 15 years in the distribution of plasma-derived products in our country, having already achieved a leading position in the Italian market.
Ethics and quality of service are the main theme of our business in Italy and in the world, since 1940 in the service of health workers and patients users of our drugs.
Our mission is to bring to Italy all Proteins Plasma derivatives produced in large and modern plants of Parets (Spain) and Los Angeles (USA) and in new plants that will soon be added, with continual improvements in yield, purity and safety and introducing those innovative, currently under research and development.
The Group Grifols collects high quality human plasma through its FDA Approved US centers plasmapheresis .
We provide the Hospital Pharmacies systems for the distribution and monitoring of drugs (Kardex), modular cleanrooms (Misterium®), equipment for the preparation of sterile infusion solutions and products for oncology (Gri-fill® 3.0) and equipment single-dose packaging of drugs destined, in hospital administration, at the bedside (Blispack).
We provide blood and plasma centers bags and equipment for transfusion, the MB-VIP service (methylene Blue Virus Inactivated Plasma) and Advanced technologies for inactivation of pathogens (viruses and bacteria) of platelet concentrates as exclusive distributors for Italy Cerus Intercept technology Inc. This technology provides the advantage to the Italian transfusion centers can also be used for virusinattivazione “in house” Plasma distributed transfusion purposes. In addition we provide medicine Transfusion Italian simple systems and efficient traceability of the transfusion of blood and plasma (Gricode®) with the benefit cost / benefit truly competitive
Francesco Carugi, Managing Director at Grifols Italy, discusses the company’s presence in the plasma, plasma products and plasma diagnostics segments, the impact of the liberalization of the Italian plasma market on…
Eugenio Aringhieri discusses Dompé’s shift in strategy towards opthalmology, instilling an innovation mindset, and broadening the company’s international horizons. Since we last interviewed you in 2009 a lot has happened:…
Pier Mannuccio Mannucci, Scientific Director of the Policlinico Foundation, describes some of the challenges the scientific community currently faces in Italy and what actions need to be taken to overcome…
The President and MD of Abiogen Pharma discusses his family company’s recent milestones, the reasons for persisting with local manufacturing, and the benefits of international partnerships. You created Abiogen back…
Ferring Italy’s CEO discusses the affiliate’s successful management strategy, new products, new partnerships, and the potential of the Italian market. When we last interviewed you in 2009, you were focused…
Francesco di Marco, General Manager for Amgen Italy, shares his view on the state of the Italian pharmaceutical sector, the turnaround the company has made in the country, and what…
Galderma Italy was a founding European affiliate for the company and has seen incredible growth in the past two decades. Managing Director Bernat Albinyana discusses the affiliate’s performance, its business…
Dr. Ermano Buratti, General Manager for Astellas Pharma in Italy, discusses the company’s evolution as it enters its second decade, the importance of partnering with the government on reimbursement, the…
In 2008 Focus Reports interviewed Mr. Federico Seghi Recli as he prepared to transform Molteni Farmaceutici into an International specialty pharma company. Today we catch up on the progress, investments…
The General Manager for Eli Lilly Italy, discusses how the company’s continuous commitment to Italy has benefited the organization, the promise the country holds if certain barriers can be overcome, and how Lilly’s…
The CEO of MSD Italy discusses the company’s promising pipeline, its plans to realize growth through the launch of innovative new drugs in 2016, the paths towards a sustainable healthcare…
The MD of the Spanish Chamber of Commerce in Italy takes stock of the prevailing business winds between the two countries as both economies complete their emergence from the shadow of…
Massimo Visentin, Country Leader for Pfizer Italy, discusses the company’s remarkable success in 2015, his hopes and ambitions for the new year, and the need of the industry and Pfizer…